Verzenio (abemaciclib) Disease area(s): Oncology Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $5.31 billion Why it sold so well: In 2024, Eli Lillys treatment for HR-positive, HER2-negative breast cancer, Verzenio, experienced substantial sales growth, with global revenues increasing by 36% year-over-year to $1.56 billion in the fourth quarter, and $5.31 billion for the full year, an increase of 37% from the previous year
Because all of these drugs can induce pronounced hypoglycemia, treatment is initiated with the lowest possible dose and carefully monitored until the dose is found that results in a fasting plasma glucose (FPG) of 110-140mg/dL
Clinical Management of Gastrointestinal Side Effects GI side effects associated with GLP-1 RAs can be effectively managed with patient-centred strategies
Visit our contact page or call us at 419.265.0404 to speak with a specialist who can guide you in choosing the right product for your needs
Insulin administration is suitably as premixed fashion for most type 2 diabetes
